A Large Sample Clinical Retrospective Study of Clopidogrel and Aspirin in the Treatment of 4071 Cases with Stable Coronary Heart Disease

doi:10.14033/j.cnki.cfmr.2015.11.010

Abstract：Objective:To investigate the clinical efficacy of Clopidogrel and Aspirin therapy in the treatment of stable coronary heart disease,in order to select the better clinical treatment.Method:4071 cases of stable coronary artery disease diagnosed in our hospital from January 2012 to January 2015 were randomly divided into the Clopidogrel group (n=2400) and the Aspirin group (n=1671).The two groups were treated with lipid-lowering, antihypertensive treatment,hypoglycemic therapy,anti-ischemic therapy.On the the basis of conventional drugs,the Clopidogrel group was given Clopidogrel,the Aspirin group was given Aspirin.14 days for a period of treatment.Then the changes platelet aggregation rate (PAR),angina pectoris, electrocardiogram clinical efficacy,neutropenia,heart function,liver function,kidney function,hemorrhage and the occurrence of adverse reactions in the two groups after 14 days were evaluated and compared.Result:After 14 d treatment,the level of PAR decreased in the Clopidogrel group was significantly larger than that of the Aspirin group(P<0.05).The deterioration rate of the Clopidogrel group was 3.3%(79/2400),which was significantly lower than 11.5%(192/1671) of the Aspirin group,the difference was statistically significant(P<0.05).The total efficiency of treatment in the Clopidogrel group was 96.7%,which was significantly higher than 78.2%of the Aspirin group,the difference was statistically significant(P<0.05).ECG curative effect assessment found that the total effective rate of the Clopidogrel group was 86.7%,which was significantly higher than 70.8%of the Aspirin group,the difference was statistically significant(P<0.05).In the course of treatment,the incidence of adverse reaction in the Clopidogrel group was 3.2%(76/2400), which was significantly lower than 10.7%(178/1671) in the Aspirin group,the difference was statistically significant(P<0.05).Conclusion:The clinical efficacy and safety of Clopidogrel in the treatment of stable coronary artery disease is better than Aspirin,and is worthy of clinical application.